aTyr plunges as lung disease drug misses main goal in late-stage study

** Shares of drug developer aTyr Pharma ATYR.O fall 83% to $1.01 premarket

** Co says its experimental drug efzofitimod did not meet the main goal in a late-stage study in patients with pulmonary sarcoidosis

** Pulmonary sarcoidosis is an inflammatory condition affecting the lungs and lymph nodes

** ATYR says it plans to engage with the U.S. FDA to determine the path forward for the drug

** Up to last close, stock up 66.6% YTD